Skip to main content
TipRanks
Go Ultimate75% OFF

BioCorRx (BICX) AI Stock Analysis

6 Followers
BICX

BioCorRx

(Other OTC:BICX)

Select Model
Rating:38Underperform
Price Target:$0.20▼(-5.26% Downside)
Action:reiterated
Date:11/16/26

Extremely weak financial performance with volatile revenue, deep losses, negative equity, and cash burn is the dominant factor. Bearish technical signals from moving averages and MACD add further pressure, while negative P/E and lack of dividends limit valuation support.

Positive Factors
Gross Profit MarginTTM gross margin of about 61% indicates the reported offerings retain meaningful gross profit despite the revenue contraction. If revenue stabilizes, this unit-level economics could support operating leverage, although current losses show that gross profit is not yet sufficient to fund the business.
Negative Factors
Severe Revenue ContractionAn approximately 86% TTM revenue decline signals substantial deterioration in demand, commercialization, or business activity. Such a sharp contraction reduces operating scale, makes fixed costs harder to absorb, and undermines confidence that the company can rebuild a durable revenue base over the next several quarters.

BioCorRx (BICX) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%BICX-24.55%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.28M
Dividend Yield
―
Average Volume (3M)
2,897
Price to Earnings (P/E)
-1.7
Beta (1Y)
-0.03
Revenue Growth
―
EPS Growth
―
Country
US
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

BioCorRx Business Overview & Revenue Model

Company Description

BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings...

How the Company Makes Money

BioCorRx’s public disclosures historically describe revenue generation tied to (a) sales of recovery- and wellness-related products and (b) service-based offerings connected to addiction treatment and related programs delivered via company initiative...

BioCorRx Financial Statement Overview

Summary

Revenue highly volatile with 85.9% TTM decline, persistent net losses exceeding $2M with margins over -400%, negative equity at -$13M, and ongoing negative operating cash flow of -$1.9M signal severe financial distress and high insolvency risk.

Income Statement

28Negative

Balance Sheet

12Very Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue111.04K797.24K7,66589.16K213.84K48.27K
Gross Profit275.96K691.38K5,99853.17K198.56K42.39K
EBITDA-3.75M-2.60M-3.59M-2.68M-3.15M-4.48M
Net Income-2.04M-3.44M-5.11M-3.77M-4.37M-5.80M
Balance Sheet
Total Assets1.79M2.15M385.94K388.89K766.59K819.98K
Cash, Cash Equivalents and Short-Term Investments18.23K139.36K88.03K65.22K68.61K85.84K
Total Debt2.30M2.13M7.11M1.81M1.68M1.77M
Total Liabilities14.82M13.67M12.74M10.34M8.97M7.78M
Stockholders Equity-13.02M-11.22M-12.12M-9.82M-8.08M-6.84M
Cash Flow
Free Cash Flow-1.90M-2.30M-1.10M-1.85M-2.04M-3.59M
Operating Cash Flow-1.90M-2.30M-1.10M-1.85M-2.04M-3.54M
Investing Cash Flow00000-50.00K
Financing Cash Flow1.63M2.35M1.12M1.85M2.02M3.08M

BioCorRx Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.21

Price Trends

50DMA0.22Negative
100DMA0.25Negative
200DMA0.31Negative

Market Momentum

MACD-0.01Positive
RSI47.93Neutral
STOCH12.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Neutral. The current price of 0.21 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 12.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BICX.

BioCorRx Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BICX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AIDXAIDX43Neutral$2.73M-0.27-387.27%―――
MNDRMNDR43Neutral$1.13M-0.04-27.32%―4.47%92.03%
BICXBICX38Underperform$6.28M-1.6626.14%―――
XWELXWEL38Underperform$5.62M-0.10317.52%―-7.58%-30.33%

* Healthcare Sector Average

Performance Comparison

-100%0%100%BICXXWELNIVFMNDRBMGLAIDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BICX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BICXBioCorRx 0.21-0.23-52.50%
XWELXwell, Inc.0.49-0.41-45.56%
NIVFNewgenivf Group Limited0.20-5764.40-100.00%
MNDRMobile-health Network Solutions Class A0.96-9.12-90.47%
BMGLBasel Medical Group Ltd0.30-13.38-97.79%
AIDX20/20 Biolabs, Inc.0.18-23.67-99.22%

BioCorRx Corporate Events

Executive/Board Changes

BioCorRx Announces Board Resignation of Director DeVarney

Neutral
Sep 4, 2026

On August 31, 2026, BioCorRx Inc. announced that Kate Beebe DeVarney, Ph.D., resigned from her role as a member of the company’s board of directors, effective the same day. The company stated that her resignation was not due to any disagreement with...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026